A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND THERAPEUTIC EFFICACY OF SAR441344 IN ADULT PATIENTS WITH PRIMARY SJOGREN'S SYNDROME (PSJS)
- Registry ID
- ACT16618
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- SANOFI-AVENTIS CANADA INC
- Start date
- 2022-06-21
- Completion date
- 2024-04-30
- Last update
- 2020-08-17
Conditions
- PRIMARY SJOGREN'S SYNDROME (PSJS)
Related clinical trials
- A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF IMVT-
1402 IN ADULT PARTICIPANTS WITH PRIMARY SJOGREN’S DISEASE WITH MODERATE TO
SEVERE SYSTEMIC DISEASE ACTIVITY
- A PHASE 3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED MULTICENTER TRIAL
WITH OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF
EFGARTIGIMOD PH20 SUBCUTANEOUS ADMINISTERED BY PREFILLED SYRINGE IN ADULT
PATIENTS WITH PRIMARY SJÖGREN¿S DISEASE
View on source registry